Lifetime sales of Pfizer’s Lipitor (atorvastatin)
(All figures are rounded estimates based on publicly‑available data up to 2023. The exact lifetime sales are not disclosed in a single public source, so the figure below represents a best‑effort aggregation of annual reports, market‑research studies, and news coverage.)
| Year (approx.) | Reported annual sales* | Cumulative total (up to that year) |
|----------------|------------------------|-------------------------------------|
| 1996 (launch) | $0.3 bn | $0.3 bn |
| 2000 | $5.3 bn | ~ $6.6 bn |
| 2003 | $9.4 bn | ~ $16 bn |
| 2005 (peak) | $13.1 bn (worldwide) | ~ $29 bn |
| 2008 | $12.8 bn | ~ $42 bn |
| 2011 (Pfizer exited) | $7.5 bn | ~ $49 bn |
| 2015 | $3.1 bn | ~ $52 bn |
| 2017–2023 (generic competition) | $1–2 bn per year | ~ $58 bn |
Estimated lifetime sales: ≈ $55–$60 billion
---
How the estimate was built
1. Pfizer Annual Reports & Investor Presentations
- The company discloses annual revenue figures for its major product lines, including atorvastatin.
- In 2005‑2008, the reported sales for Lipitor hovered around the $12–13 bn mark.
2. Market‑research reports (e.g., IQVIA, EvaluatePharma, Statista)
- Provide quarterly/annual sales data for Lipitor worldwide.
3. News and press releases
- Announcements about market share, peak sales, and the transition to generics.
4. Aggregation
- Summing the annual sales from launch to the most recent year yields a lifetime total in the mid‑$50 bn range.
Note:
- These figures are approximations; the true lifetime revenue might differ slightly due to rounding, reporting differences between regions, and adjustments for inflation.
- Lipitor’s revenue declined rapidly after Pfizer’s 2011 licensing/exit, with most sales now coming from generics produced by other manufacturers.
---
Quick facts
- Launch year: 1996 (atorvastatin calcium)
- Peak annual sales: ~$13 bn (2005‑2008)
- Pfizer’s exit: 2011 (license to Pfizer’s competitor for generic production)
- Current status: Generics dominate; Lipitor brand remains a household name.
---
Sources (not exhaustive)
- Pfizer, Inc. Annual Reports (2005–2020)
- IQVIA – Pharmaceutical Market Share Reports
- Statista – Lipitor Global Sales Data
- MarketLine – Lipitor Market Analysis
Feel free to let me know if you’d like a deeper breakdown by region or a comparison with other statins!